News NICE finalises support for CSL's HAE therapy Andembry CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.
News FDA green lights CSL's once-monthly HAE drug Andembry CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.
News EU approves CSL's once-monthly HAE drug Andembry The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.
News FDA reveals real-world pilot for digital health tools The FDA is rolling out a pilot programme that could make it easier to bring digital health technologies for chronic diseases to market more quickly.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.